Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-world data may reveal true value of abemaciclib for advanced breast cancer

NCT ID NCT04985058

Recruiting now Disease control Sponsor: Hellenic Cooperative Oncology Group Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tracks 108 patients with HR-positive, HER2-negative advanced breast cancer who are receiving abemaciclib combined with hormone therapy. Researchers are collecting real-world data on how long patients live without their cancer worsening, overall survival, and side effects. The goal is to see if the benefits seen in clinical trials hold up in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
abemaciclib combined with endocrine therapy
What this could lead to
If successful, this study could confirm that abemaciclib plus hormone therapy works well in everyday practice, not just in controlled trials.
What could go wrong
This is an observational study, not a controlled experiment, so results may be influenced by patient differences and cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hellenic Oncology Cooperative Group

    RECRUITING

    Athens, Greece

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.